40. Approaches to immunology, inflammation, and oncology, Dr. Luisa Salter-Cid, CSO, Gossamer Bio

40. Approaches to immunology, inflammation, and oncology, Dr. Luisa Salter-Cid, CSO, Gossamer Bio

Dr. Salter-Cid brings to Gossamer Bio over 20 years of drug discovery experience in the biotech and pharmaceutical industries and spent the last 13 years at Bristol Myers Squibb (“BMS”) in increasing positions of responsibility, including Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery. In this position, she oversaw several biology groups that focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at BMS, Dr. Salter-Cid led teams that advanced more than 20 compounds into clinical development. She was also Chair of the Immunoscience Target Science Team (TST) and a core member of Early Development, Strategy and Licensing teams for both Immunology and Immuno-Oncology. Additionally, she was the scientific lead on several of BMS’ acquisitions and licensing deals and sat on multiple Joint Research Committees and Scientific Advisory Boards. Prior to joining BMS, she was a Senior Project Leader at La Jolla Pharmaceuticals where she led discovery projects. Dr. Salter-Cid also held positions at Genset Corp and Johnson & Johnson. She is an author of over 70 publications and patents and holds a Ph.D. in Immunology from the University of Miami.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(265)

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Synopsis: The drug discovery industry faces a persistent challenge: 9 out of 10 drugs entering the clinic fail, underscoring the need for a better path from biological insight to transformative medi...

24 Sep 45min

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Synopsis: What does it take to turn a once-fringe scientific idea into a new approach to drug discovery—and build a biotech company around it for the long haul? In this episode of Biotech 2050, hos...

16 Sep 38min

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, p...

3 Aug 47min

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient l...

22 Jul 34min

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Jun 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Mai 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mar 14min

Populært innen Vitenskap

fastlegen
romkapsel
jss
tingenes-tilstand
liberal-halvtime
sinnsyn
villmarksliv
forskningno
rekommandert
rss-paradigmepodden
fjellsportpodden
grunnstoffene
nordnorsk-historie
rss-nysgjerrige-norge
smart-forklart
rss-inn-til-kjernen-med-sunniva-rose
rss-rekommandert
psykopoden
tidlose-historier
rss-overskuddsliv